Pfenex inks vaccine development deal with Merck

AP News
|
Posted: Dec 14, 2009 5:47 PM

Biotech company Pfenex said Monday it has licensed certain technology to Merck & Co. for the co-development of potential vaccines.

Under terms of the agreement Pfenex is eligible to receive up to $52 million in direct payments, as well as royalties on any sales of vaccines.

Scientists from both companies will collaborate on proteins strains used in vaccine development.